Trasylol Continues To Cause Heartache For Bayer
Bayer AG may soon face regulatory scrutiny over Trasylol, with the U.S. Food and Drug Administration set to hear testimony from a group of outside experts as to whether the blood-clotting...To view the full article, register now.
Already a subscriber? Click here to view full article